Journal of Neurology

, Volume 257, Issue 10, pp 1703–1707 | Cite as

Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta

  • Armando Sena
  • Klaus Bendtzen
  • Maria J. Cascais
  • Rui Pedrosa
  • Véronique Ferret-Sena
  • Elisa Campos
Original Communication


Interferon-beta (IFN-beta) therapy for multiple sclerosis (MS) is associated with a potential for induction of neutralizing antibodies (NAbs). Because immune reactivity depends on changes in lipoprotein metabolism, we investigated whether plasma lipoprotein profiles could be associated with the development of NAbs. Thirty-one female MS patients treated with subcutaneously administered IFN-beta were included. Demographic and clinical characteristics were compared between NAbs response groups using t tests for continuous and logistic regression analysis and Fisher’s exact tests for categorical data, respectively. Multivariate logistic regression was used to evaluate the effect of potential confounders. Patients who developed NAbs had lower apoE levels before treatment, 67 (47–74) mg/L median (interquartile range), and at the moment of NAb analysis, 53 (50–84) mg/L, in comparison to those who remained NAb-negative, 83 (68–107) mg/L, P = 0.03, and 76 (66–87) mg/L, P = 0.04, respectively. When adjusting for age and smoking for a one-standard deviation decrease in apoE levels, a 5.6-fold increase in the odds of becoming NAb-positive was detected: odds ratios (OR) 0.18 (95% CI 0.04–0.77), P = 0.04. When adjusting for apoE, smoking habit became associated with NAb induction: OR 5.6 (95% CI 1.3–87), P = 0.03. These results suggest that apoE-containing lipoprotein metabolism and, possibly, tobacco smoking may be associated with risk of NAb production in female MS patients treated with IFN-beta.


Multiple sclerosis Interferon-beta Neutralising antibodies Lipoproteins Apolipoprotein E Tobacco smoking 


  1. 1.
    Hartung HP, Polman C, Bertolotto A et al (2007) Neutralising antibodies to interferon β in multiple sclerosis: expert panel report. J Neurol 254:827–837CrossRefPubMedGoogle Scholar
  2. 2.
    Bendtzen K, Kromminga A (2008) Immunogenicity of interferon-beta. In: van de Weert M, Moller EH (eds) Biotechnology: pharmaceutical aspects vol VIII. Immunogenicity of biopharmaceuticals. Springer, New York, pp 127–136Google Scholar
  3. 3.
    Hoffmann S, Cepok S, Grummel V et al (2008) HLA-DRB1*0401 and HLA-DRB1 *0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Hum Genet 83:219–227CrossRefPubMedGoogle Scholar
  4. 4.
    Gilli F, Valentino P, Caldano M (2008) Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology 71:1940–1947CrossRefPubMedGoogle Scholar
  5. 5.
    Lo JC, Wang Y, Tumanov AV et al (2007) Lymphotoxin alpha receptor-dependent control of lipid homeostasis. Science 316:285–288CrossRefPubMedGoogle Scholar
  6. 6.
    Getz SG, Reardon CA (2009) Apoprotein E as a lipid transport and signalling protein in the blood, liver, and artery wall. J Lipid Res S156–S161Google Scholar
  7. 7.
    Giubilei F, Antonini G, De Legges S et al (2002) Blood cholesterol and MRI activity in first episode suggestive of multiple sclerosis. Acta Neurol Scand 106:109–112CrossRefPubMedGoogle Scholar
  8. 8.
    Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H (2009) Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 15:399–402CrossRefPubMedGoogle Scholar
  9. 9.
    McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on diagnosis of multiple sclerosis. Ann Neurol 50:121–127CrossRefPubMedGoogle Scholar
  10. 10.
    Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  11. 11.
    Roxburgh RH, Seaman SR, Masterman T et al (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64:1144–1151PubMedGoogle Scholar
  12. 12.
    Rio J, Nos C, Tintoré M et al (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352CrossRefPubMedGoogle Scholar
  13. 13.
    Sorensen PS, Ross C, Clemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191CrossRefPubMedGoogle Scholar
  14. 14.
    Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMedGoogle Scholar
  15. 15.
    Sena A, Couderc Ferret-SenaV et al (2009) Apolipoprotein E polymorphism interacts with cigarette smoking in progression of multiple sclerosis. Eur J Neurol l16:832–837CrossRefGoogle Scholar
  16. 16.
    Comabella M, Lunemann JD, Rio J et al (2009) A type I interferon signature in monocytes associated with poor response to interferon-beta in multiple sclerosis. Brain 132:3353–3365CrossRefPubMedGoogle Scholar
  17. 17.
    Carlsson J, Armstrong VW, Reiber H et al (1991) Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin Chem Acta 196:167–176CrossRefGoogle Scholar
  18. 18.
    Feng-Qiao L, Sempowski GD, McKenna SE et al (2006) Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in murine model of multiple sclerosis. J Pharmacol Exp Ther 318:956–965CrossRefGoogle Scholar
  19. 19.
    Li L, Thompson PA, Kitchens RL (2008) Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res 49:1782–1793CrossRefPubMedGoogle Scholar
  20. 20.
    Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M (2007) An association between autoreactive antibodies and anti-interferon-β antibodies in multiple sclerosis. Mult Scler 13:895–899CrossRefPubMedGoogle Scholar
  21. 21.
    Sena A, Pedrosa R, Graça Morais M (2004) Statins for multiple sclerosis. Lancet 364:412CrossRefPubMedGoogle Scholar
  22. 22.
    Sapori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2:372–377CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Armando Sena
    • 1
    • 2
  • Klaus Bendtzen
    • 3
  • Maria J. Cascais
    • 1
  • Rui Pedrosa
    • 2
  • Véronique Ferret-Sena
    • 4
  • Elisa Campos
    • 1
  1. 1.CEDOC, Departamento de Bioquímica, Faculdade de Ciências MédicasUniversidade Nova de LisboaLisbonPortugal
  2. 2.Departamento de NeurociênciasCentro Hospitalar de Lisboa-CentralLisbonPortugal
  3. 3.Institute for Inflammation Research IIR7521Rigshospitalet National University HospitalCopenhagenDenmark
  4. 4.Departamento de FisiologiaCentro de Investigação Interdisciplinar Egas MonizMonte de CaparicaPortugal

Personalised recommendations